---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268185"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:38:28.340099+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen

## Summary
- Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.
- Commission of up to 3.0% on gross proceeds; company controls timing and size of sales.
- Replaces existing 2021 ATM facility once new shelf registration statement becomes effective.
- No sales permitted until the registration statement is declared effective by the SEC.

## SEC filing metadata
- accession: 0001193125-23-268185
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/0001193125-23-268185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/d527002d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268185
- JSON: https://secwatch.observer/filing/0001193125-23-268185.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.